Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects. Local targets link to admitted publications; unresolved targets remain external evidence.
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
10.1210/jcem-63-2-492 · 1986 · External reference
10.1111/j.2040-1124.2010.00022.x · 2010 · Admitted local publication
The biology of incretin hormones
10.1016/j.cmet.2006.01.004 · 2010 · External reference
The physiology of glucagon-like peptide 1
10.1152/physrev.00034.2006 · 2007 · External reference
Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance
10.1056/nejm199201023260104 · 1992 · External reference
Increased insulin concentrations in nondiabetic offspring of diabetic parents
10.1056/nejm198811173192001 · 1988 · External reference
A two-step model for development of non-insulin-dependent diabetes
10.1016/0002-9343(91)80165-i · 1991 · External reference
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
10.1007/bf02427280 · 1986 · External reference
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients
10.2337/db07-1315 · 2008 · External reference
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
10.1172/jci116186 · 1993 · External reference
The pathogenesis of NIDDM involves a defective expression of the GIP receptor
10.1007/s001250050779 · 1997 · External reference
Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice
10.1073/pnas.96.26.14843 · 1999 · External reference
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
10.1038/nm727 · 2002 · External reference
Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice
10.2337/diabetes.32.5.433 · 1983 · External reference
Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels
10.1007/bf00429703 · 1978 · External reference
A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice
10.1152/ajpendo.00358.2007 · 2008 · External reference
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
10.2337/diabetes.50.3.609 · 2001 · External reference
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance
10.2337/db07-1124 · 2008 · External reference
Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action
10.1007/s00125-008-0951-x · 2008 · External reference
10.1111/j.2040-1124.2010.00010.x · 2010 · Admitted local publication
Comparison of measured and estimated indices of insulin sensitivity and beta cell function: impact of ethnicity on insulin sensitivity and beta cell function in glucose-tolerant and normotensive subjects
10.1210/jc.86.4.1620 · 2001 · External reference
Asian’s big problem
10.1038/nm0404-325 · 2004 · External reference
The insulinogenic index in secondary diabetes
10.1055/s-0028-1093759 · 1975 · External reference
Factors responsible for elevation of one hour postchallenge plasma glucose levels in Japanese men
10.1016/j.diabres.2008.04.011 · 2008 · External reference
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
10.2337/diab.28.12.1039 · 1979 · External reference
Definition, diagnosis and classification of diabetes mellitus and its complications. Part1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s · 1998 · External reference
Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients
10.1111/j.1464-5491.2008.02651.x · 2009 · External reference
Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell
10.1210/en.2008-0726 · 2009 · External reference
Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
10.1007/bf00280883 · 1985 · External reference
Homeostasis model assessment as a clinical index of insulin resistance
10.2337/diacare.22.11.1911 · 1999 · External reference
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euroglycemic insulin clamp
10.2337/diacare.22.9.1462 · 1999 · External reference
Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus
10.1172/jci105534 · 1967 · External reference
Forearm metabolism in obesity and its response to intra-arterial insulin. Characterization of insulin resistance and evidence for adaptive hyperinsulinism
10.1172/jci104676 · 1962 · External reference
Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
10.2337/diacare.14.3.173 · 1991 · External reference
Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes
10.1016/j.bbrc.2010.01.134 · 2010 · External reference
Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes
10.1507/endocrj.k09e-269 · 2009 · External reference
Relation between gastric empting of glucose and plasma concentrations of glucagon-like peptide-1
10.1016/s0196-9781(98)00052-7 · 1998 · External reference
Splanchnic lipolysis in human obesity
10.1172/jci21047 · 2004 · External reference
Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia
10.2337/diacare.26.4.1211 · 2003 · External reference
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial
10.2337/diacare.27.6.1335 · 2004 · External reference
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes
10.2337/dc06-0703 · 2006 · External reference
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
10.1016/j.diabres.2008.03.018 · 2008 · External reference
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
10.1016/j.diabres.2007.08.021 · 2007 · External reference
Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men
10.1016/j.metabol.2005.07.006 · 2006 · External reference
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge
10.1038/ng.521 · 2010 · External reference
